PROVECTUS PHARMA ADDS M.D. ANDERSON AS PHASE 2 US TRIAL CENTER

BW)(TN-PROVECTUS-PHARMA)(PVCT.OTCBB) Provectus Pharmaceuticals Adds M.D. Anderson as First U.S. Center to Phase 2 Clinical Trial Of PV-10

Expansion of Phase 2 Trial for Metastatic Melanoma Continues

Pharmaceutical Writers/Business Editors

KNOXVILLE, Tenn.--(BUSINESS WIRE) - Jul. 21, 2008-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at the M.D. Anderson Cancer Center, in Houston, TX (http://www.mdanderson.org).

Professor Merrick Ross, MD, is the lead investigator of the team at M.D.

Anderson. This first U.S. center joins those already announced in Sydney and Brisbane, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several additional sites in the United States.

Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will evaluate efficacy of PV-10 in a total of 80 subjects. In the study, PV-10 is being injected into up to 20 tumors in each subject. Additional treatment with PV-10 may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for one (1) year, allowing data to be gathered for assessment of objective response rate, progression free survival, quality of life and safety. An interim assessment of safety and efficacy will be conducted after treatment of the first 20 and first 40 subjects. Details of the study are available at the www.ClincalTrials.gov clinical trials registry.

"Opening the study at this premier U.S. center is another major milestone in the expansion of our Phase 2 program in melanoma to encompass leading clinical sites in the U.S. and Australia," said Craig Dees, Ph.D., CEO of Provectus. "We are extremely pleased to have an investigator of Dr. Ross' extraordinary caliber join our team, and to have the extraordinary resources of M.D.

Anderson available for melanoma patients who elect to undergo PV-10 therapy in the U.S."

According to the American Cancer Society, more than 62,000 people are expected to be diagnosed in the U.S. in 2008 with melanoma, the most serious form of skin cancer, leading to over 8,000 deaths this year.

Dees continued, "While we are delighted with our progress in Australia, we are especially excited that PV-10 will now be available to patients in the U.S. that meet the clinical trial parameters. Being able to make the drug available through trials in the U.S. is very fulfilling to us at Provectus, both for the value it demonstrates to our shareholders and, as inventors of PV-10, to see it available to our neighbors with this devastating disease."About ProvectusPharmaceuticals, Inc. (www.pvct.com) Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis and for atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.ClinicalTrials.gov.

The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology.

For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. via the information provided.

About M.D. Anderson Cancer Center (www.mdanderson.org) The M. D. Anderson Cancer Center was created in 1941 as a component of The University of Texas System. It is one of the nation's original three Comprehensive Cancer Centers designated by the National Cancer Act of 1971, and is one of 39 National Cancer Institute-designated Comprehensive Cancer Centers today. In 2007, U.S.

News and World Report ranked M. D. Anderson as the top hospital in the nation for cancer care, a designation it has achieved five times in the past eight years. Since 1944, nearly 700,000 patients have turned to M.

D. Anderson for cancer care in the form of surgery, chemotherapy, radiation therapy, immunotherapy, or combinations of these and other treatments. This multidisciplinary approach to treating cancer was pioneered at M.?D. Anderson. Because they focus only on cancer, experts at M.D. Anderson are renowned for their ability to treat all types of cancer, including rare or uncommon diseases. In 2008, more than 79,000 people with cancer will receive care at M. D. Anderson. About one-third of these patients come from outside Texas seeking the knowledge-based care that has made M.?D. Anderson so widely respected. More than 11,000 patients participated in therapeutic clinical research exploring novel treatments in Fiscal Year 2006, making it the largest such program in the nation.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Provectus Pharmaceuticals, Inc.Peter R. Culpepper, CFO 866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse, VP ? Investor RelationsBill Gordon, SVP ? Media Relations 212-564-4700